Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2022-10-04 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement by Zealand Pharma regarding the completion of a directed share issue and private placement. It details the number of shares issued, the subscription price, the gross proceeds raised, and the intended use of funds. It also outlines the timeline for listing and settlement. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific capital increase and issuance of new shares.
2022-10-04 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 98% confidence The document is a company announcement from Zealand Pharma detailing the launch of an offering of new shares through a directed issue and private placement (accelerated bookbuilding process). This action directly relates to raising capital and changing the company's share structure. Based on the definitions, this falls under 'Capital/Financing Update' (CAP) as it describes fundraising activities and the issuance of new shares. While it involves shares, the primary focus is the financing event itself, rather than a general share issue announcement (SHA) or a transaction in own shares (POS, which usually implies buybacks). Since it is a direct announcement of a capital raise, CAP is the most appropriate classification.
2022-10-04 English
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the total number of shares and voting rights in Zealand Pharma as of September 30, 2022. This is a regulatory requirement under the Danish Capital Markets Act following changes in share capital. While it relates to share capital, it is a standard regulatory disclosure of share counts rather than a new share issuance or a transaction in own shares (buyback). Given the nature of the disclosure as a mandatory regulatory update, it fits best under the 'Regulatory Filings' (RNS) category.
2022-09-30 English
Earnings Release 2022
Earnings Release Classification · 100% confidence The document is titled "Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide..." and is labeled as a 'Company announcement – No. 41 / 2022'. It details the topline results of a clinical trial (Phase 3 EASE 1), including primary endpoints, statistical significance, safety profile, and mentions an upcoming conference call to discuss these results. This structure—announcing key financial or operational milestones (like trial results) followed by details and a call invitation—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses purely on clinical trial results and not comprehensive quarterly financials, it is best classified as an Earnings Release (ER) as it serves as the primary announcement of a major operational/development milestone, often released concurrently with or instead of a traditional earnings report for biotech firms. It is not a full Annual Report (10-K), an Interim Report (IR), or just a simple announcement of a report publication (RPA). Q3 2022
2022-09-30 English
Zealand Pharma grants warrants to employees in Denmark
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding the granting of warrants to employees. This involves the issuance of new shares or rights to subscribe for shares, which falls under capital changes. While it mentions remuneration policy, it is specifically an announcement of a share-based incentive grant (warrants), which is best classified as a share issue or capital change announcement.
2022-09-13 Danish
Share Issue/Capital Change 2022
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement dated September 8, 2022, detailing an increase in share capital resulting from the exercise of employee warrants. This action directly involves changes to the company's outstanding shares and capital structure. This aligns precisely with the definition of 'Share Issue/Capital Change' (Code: SHA), which covers announcements regarding new share issues or capital structure changes. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific corporate action related to equity.
2022-09-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.